TEXT SIZE

SEARCH

Corporate Philosophy & Corporate Mission

The Tsumura Group will engage in management that is rooted in basic principles such as our corporate philosophy, “The Best of Nature and Science,” and our corporate mission, “To contribute to the unparalleled medical therapeutic power of the combination of Kampo medicine and Western medicine.” Our Kampo and crude drug business has no equivalent in the world. Whether in production, R&D or sales, all our employees fulfil their work functions with the highest degree of professionalism, and they are required to determine and pursue their own goals. For this reason, we have established the Tsumura-DNA pyramid, which is centered on individual employees, and we are working to cultivate human resources* across the entire Tsumura Group.

Tsumura’s Corporate Philosophy

  • Corporate Philosophy  The Best of Nature and Science
  • Corporate Mission  To contribute to the unparalleled medical therapeutic power of the combination of Kampo medicine and Western medicine

TSUMURA-DNA PYRAMID

large image

Vision for 2021 and the New Medium-Term Management Plan

Our long-term business vision envisages the state of our group ten years from now, and our Vision for 2021 consists of promoting corporate value creation through a three-part vision: (1) The “Kampo” Company, (2) The “People” Company, and (3) The “Global Niche” Company.

Aim to be a value-creation company that contributes to people’s health through its Kampo business

The “Kampo” Company

Contributing to creating a healthcare environment where all patients can receive treatment that includes “Kampo” medicine where appropriate in any healthcare institution or medical specialty in Japan.

The “People” Company

“Kampo” medicine is a pioneering field with no previous examples to build on worldwide. Therefore, we shall evolve into a corporate group comprised of “people” with professional skills that can independently pave the way forward for our Kampo business and is trusted by all.

The “Global Niche” Company

Leveraging the technology and know-how of the Tsumura Group to their full extent, we will take on the challenge of developing and launching TU-100 (Daikenchuto) in the U.S. pharmaceutical market as well as creating new businesses in China.